DOCSLIB.ORG

Index to the NLM Classification 2011

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

National Library of Medicine Classification 2011 Index Disease see Tyrosinemias 1-8 5,12-diHETE see Leukotriene B4 1,2-Benzopyrones see Coumarins 5,12-HETE see Leukotriene B4 1,2-Dibromoethane see Ethylene Dibromide 5-HT see Serotonin 1,8-Dihydroxy-9-anthrone see Anthralin 5-HT Antagonists see Serotonin Antagonists 1-Oxacephalosporin see Moxalactam 5-Hydroxytryptamine see Serotonin 1-Propanol 5-Hydroxytryptamine Antagonists see Serotonin Organic chemistry QD 305.A4 Antagonists Pharmacology QV 82 6-Mercaptopurine QV 269 1-Sar-8-Ala Angiotensin II see Saralasin 7S RNA see RNA, Small Nuclear 1-Sarcosine-8-Alanine Angiotensin II see Saralasin 8-Hydroxyquinoline see Oxyquinoline 13-cis-Retinoic Acid see Isotretinoin 8-Methoxypsoralen see Methoxsalen 15th Century History see History, 15th Century 8-Quinolinol see Oxyquinoline 16th Century History see History, 16th Century 17 beta-Estradiol see Estradiol 17-Ketosteroids WK 755 A 17-Oxosteroids see 17-Ketosteroids A Fibers see Nerve Fibers, Myelinated 17th Century History see History, 17th Century Aardvarks see Xenarthra 18th Century History see History, 18th Century Abate see Temefos 19th Century History see History, 19th Century Abattoirs WA 707 2',3'-Cyclic-Nucleotide Phosphodiesterases QU 136 Abbreviations 2,4-D see 2,4-Dichlorophenoxyacetic Acid Chemistry QD 7 2,4-Dichlorophenoxyacetic Acid General P 365-365.5 Organic chemistry QD 341.A2 Library symbols (U.S.) Z 881 2',5'-Oligoadenylate Polymerase see Medical W 13 2',5'-Oligoadenylate Synthetase By specialties (Form number 13 in any NLM 2',5'-Oligoadenylate Synthetase QU 141 schedule where applicable) 2-5A Synthetase see 2',5'-Oligoadenylate Synthetase Organizations (General) AS 8 2-Acetamidofluorene see 2-Acetylaminofluorene Periodical titles Z 6945.A2 2-Acetylaminofluorene QZ 202 Science (General) Q 179 2-Aminoethylisothiuronium Bromide see Particular languages, by language in appropriate LC beta-Aminoethyl Isothiourea schedule 2-Bromoergocryptine see Bromocriptine Abdomen WI 900-970 2-Chlorethanol see Ethylene Chlorohydrin General Surgery WI 900-970 2-Chloroacetophenone see Radiography see Radiography, Abdominal WI 900 omega-Chloroacetophenone Abdomen, Acute WI 900 2-Chloroethyl Alcohol see Ethylene Chlorohydrin Infant or child WI 900 2-Hydroxyphenethylamine QU 61 Abdominal Cavity WI 900 2-Mercaptoethanesulfonate see Mesna Abdominal Cramps see Colic 2-Phenylethanolamine see Abdominal Epilepsy see Epilepsies, Partial 2-Hydroxyphenethylamine Abdominal Injuries WI 900 2-Propanol Abdominal Muscles WI 900 Pharmacology QV 82 See also Abdominal Wall WI 900 20th Century History see History, 20th Century Abdominal Neoplasms WI 970 21-Hydroxyprogesterone see Desoxycorticosterone Nursing WY 156 21st Century History see History, 21st Century Abdominal Pain WI 147 3,4-Benzopyrene see Benzo(a)pyrene See also Colic 3,4-Methylenedioxyamphetamine Abdominal Pregnancy see Pregnancy, Abdominal Abuse see Amphetamine-Related Disorders WM Abdominal Wall WI 900 275 See also Abdominal Muscles WI 900 Pharmacology, etc. QV 102 Abducens Nerve WL 330 3-Isoleucine,8-Leucine Vasopressin see Oxytocin Abiogenesis see Biogenesis 4-Aminobutyrate Transaminase QU 141 Abnormal Karyotype see Chromosome Aberrations 4-Aminobutyric Acid see gamma-Aminobutyric Acid Abnormal Reflex see Reflex, Abnormal 4-Aminohippuric Acid see p-Aminohippuric Acid Abnormalities, Drug-Induced QS 679 4 Hydroxyphenylpyruvate Dioxygenase Deficiency See also Teratogens ALWAYS CONSULT MAIN SCHEDULES. USE NUMBER ASSIGNED ONLY WHEN SUBJECT REPRESENTS MAJOR EMPHASIS OF WORK BEING CLASSIFIED I-1 National Library of Medicine Classification 2011 Index Abnormalities, Multiple QS 675 Other localities, by site See also Mental Retardation Pelvic WP 155 Abnormalities, Radiation-Induced QS 681 Periapical see Periapical Abscess WU 230 Abnormalities, Severe Teratoid QS 675 Puerperal WQ 505 Abnormality, Torsion see Torsion Abnormality Subphrenic see Subphrenic Abscess WI 575 Abomasum QL 862 See also Empyema Aborigines see Oceanic Ancestry Group Abscess, Amebic see Amebiasis Aborted Fetus WQ 210 Abscess, Amebic, Hepatic see Liver Abscess, In research (general), see Fetal Research W Amebic 20.55.F4 Abscess, Cerebral see Brain Abscess Specific topics, with the topic Abscess, Hepatic see Liver Abscess See also Abortion, Induced Abscess, Hepatic, Amebic see Liver Abscess, See also Abortion, Spontaneous WQ 225 Amebic Abortifacient Agents QV 175 Abscess, Liver, Amebic see Liver Abscess, Amebic See also Oxytocics Abscess, Periapical see Periapical Abscess Abortifacient Agents, Nonsteroidal QV 175 Abscess, Pulmonary see Lung Abscess Abortifacient Agents, Steroidal QV 175 Abscess, Subdiaphragmatic see Subphrenic Abortion, Criminal W 867 Abscess Abortion, Habitual WQ 225 Abscess, Subphrenic see Subphrenic Abscess See also Fetal Death Absence Seizures see Epilepsy, Absence Abortion, Illegal see Abortion, Criminal Absenteeism Abortion, Incomplete WQ 225 School WA 350 Abortion, Induced Workplace HD 5115-5115.2 Legal aspects WQ 32-33 Absorption Public health aspects WA 550 Immunochemistry QW 504.5 Religious and social aspects HQ 767-767.52 Intestinal see Intestinal Absorption WI 402 Technique WQ 440 Of drugs QV 38 See also Aborted Fetus Of foods WI 102 Abortion, Legal Of gases QC 162 General WQ 440 Skin see Skin Absorption WR 102 Public health aspects WA 550 Of other substances, with the substance Abortion, Missed WQ 225 See also Intestinal Absorption Abortion on Demand see Abortion, Legal See also Skin Absorption Abortion, Recurrent see Abortion, Habitual Absorption, Intestinal see Intestinal Absorption Abortion, Septic WQ 256 Absorption, Skin see Skin Absorption Veterinary SF 887 Abstinence Syndrome, Neonatal see Neonatal Abortion, Spontaneous WQ 225 Abstinence Syndrome Drugs provoking see Abortifacient Agents QV 175 Abstracting and Indexing as Topic Z 695.9-695.94 Medicolegal aspects W 867 Abstracting as Topic see Abstracting and Indexing Religious and social aspects HQ 767-767.52 as Topic See also Aborted Fetus Abstracts See also Abortifacient Agents Of subjects not represented in NLM's classification, Abortion, Therapeutic LC's Z schedule General WQ 440 Of subjects represented in NLM's classification, Public health aspects WA 550 appropriate classification number preceded by the Abortion, Threatened WQ 225 letter Z Abortion, Veterinary SF 887 See also Bibliography Abreaction WM 420.5.A2 See also Indexes Abruptio Placentae WQ 212 See also Resource Guides Abscess WC 195 Abuse of Health Services see Health Services General (requiring surgery) WO 140 Misuse Bone WE 251 Abuse Reporting see Mandatory Reporting Cerebral see Brain Abscess WL 351 Abused Women see Battered Women General Surgery WO 140 Academic Dissertations as Topic see Dissertations, Liver see Liver Abscess WI 730 Academic as Topic Lung see Lung Abscess WF 651 Academic Medical Centers WX 27-28 ALWAYS CONSULT MAIN SCHEDULES. USE NUMBER ASSIGNED ONLY WHEN SUBJECT REPRESENTS MAJOR EMPHASIS OF WORK BEING CLASSIFIED I-2 National Library of Medicine Classification 2011 Index History WX 11 Accidents, Aviation WD 740 Of specific medical centers, WX 27-28 Accidents, Home WA 288 Academies and Institutes AS Accidents, Industrial see Accidents, Occupational Government institutes Accidents, Nuclear see Radioactive Hazard Release (Form numbers 23-24 in any NLM schedule where Accidents, Nuclear Reactor see Radioactive Hazard applicable) Release For other particular purposes, by subject Accidents, Occupational WA 485-491 (Form numbers 23-24 in any NLM schedule where Of the eye WW 505-525 applicable) See also special topics under Accidents History (Form numbers 23-24 in any NLM schedule See also Occupational Diseases where applicable) Accidents, Radiation see Radioactive Hazard Acanthocephala QX 200 Release Acantholysis Bullosa see Epidermolysis Bullosa Accidents, Traffic WA 275 Acanthosis Nigricans WR 265 Prevention & control WA 275 Acarbose WK 825 Acclimation see Acclimatization Acari QX 473 Acclimatization QT 145 Acariasis see Mite Infestations Cold climate QT 160 Acarina see Acari Hot climate QT 150 Acarus see Mites Tropical climate QT 150, etc. Acceleration WD 720 See also Desert Climate QT 150, etc. Accelography see Kinetocardiography Accommodation, Ocular WW 109 Acceptability of Health Care see Patient Acceptance Accountable Health Plans see Managed Competition of Health Care Accounting Access to Health Care see Health Services Dental administration WU 77 Accessibility Hospital administration WX 157 Access to Information In other specific fields, by subject Medical Records WX 173 Medical administration W 80 Special topics, by subject Nursing administration WY 77 See also Civil Rights JC 571-628 Pharmacy administration QV 736 Accessibility of Health Services see Health Services Accreditation Accessibility Dentists WU 40 Accessory Cells, Immunologic see Hospitals (General) WX 40 Antigen-Presenting Cells Special (Form numbers 27-28 in any NLM Accessory Nerve WL 330 schedule where applicable) Accessory Sex Organs see Genitalia Physicians W 40 Accessory Sex Organs, Female see Genitalia, Other institutes, etc. (Form numbers 23-24 in any Female NLM schedule where applicable) Accessory Sex Organs, Male see Genitalia, Male Other professionals (Form number 21 in any NLM Accident Insurance see Insurance, Accident schedule where applicable) Accident Prevention WA 250-288 Schools (Form numbers 18 or other appropriate General WA 250 education number in any NLM schedule where In hospitals WX 185 applicable) In workplace see Accidents, Occupational WA See also Certification
Recommended publications

  • Breast Cysts

    Beaumont Hospital Patient Information on Breast Cysts PRINTROOM PDF 23012017 SUP190B What are breast cysts? The breasts are made up of lobules (milk- producing glands) and ducts (tubes that carry milk to the nipple), surrounded by fatty and supportive tissue. Sometimes fluid-filled sacs develop in the breast tissue. These are breast cysts. It’s thought that they develop naturally as the breast ages and changes. Although you can develop breast cysts at any age, they are most common in women over 35 who haven’t yet reached menopause. They occur more frequently as women approach the menopause and usually resolve or are less frequent after it. However, they may persist or develop in women who take hormone replacement therapy (HRT) after menopause. Cysts can feel soft if they are near the surface of the skin, or like a hard lump if they’re deeper in the breast tissue. They can develop anywhere in the breast, but are more commonly found in the upper half. For some women cysts can feel uncomfortable or even painful. Before a period cysts may become larger, and feel sore and tender. It’s common to develop one or more cysts either in one breast or both breasts –and this is nothing to worry about. It is also common to have many cysts without knowing about them. How are they found? Cysts usually become noticeable as a lump in the breast, or are sometimes found by chance when you have a breast examination or routine mammography. When you have a breast examination your GP will sometimes be able to say whether the lump feels like a cyst.
  • Microsporum Canis Genesig Standard

    Microsporum Canis Genesig Standard

    Primerdesign TM Ltd Microsporum canis PQ-loop repeat protein gene genesig® Standard Kit 150 tests For general laboratory and research use only Quantification of Microsporum canis genomes. 1 genesig Standard kit handbook HB10.04.10 Published Date: 09/11/2018 Introduction to Microsporum canis Microsporum canis is a zoophilic dermatophyte which is responsible for dermatophytosis in dogs and cats. They cause superficial infections of the scalp (tinea capitis) in humans and ringworm in cats and dogs. They belong to the family Arthrodermataceae and are most commonly found in humid and warm climates. They have numerous multi-celled macroconidia which are typically spindle-shaped with 5-15 cells, verrucose, thick-walled, often having a terminal knob and 35-110 by 12-25 µm. In addition, they produce septate hyphae and microconidia and the Microsporum canis genome is estimated at 23 Mb. The fungus is transmitted from animals to humans when handling infected animals or by contact with arthrospores contaminating the environment. Spores are very resistant and can live up to two years infecting animals and humans. They will attach to the skin and germinate producing hyphae, which will then grow in the dead, superficial layers of the skin, hair or nails. They secrete a 31.5 kDa keratinolytic subtilisin-like protease as well as three other subtilisin- like proteases (SUBs), SUB1, SUB2 and SUB3, which cause damage to the skin and hair follicle. Keratinolytic protease also provides the fungus nutrients by degrading keratin structures into easily absorbable metabolites. Infection leads to a hypersensitive reaction of the skin. The skin becomes inflamed causing the fungus to move away from the site to normal, uninfected skin.
  • Clomifene Citrate(BANM, Rinnm) ⊗

    Clomifene Citrate(BANM, Rinnm) ⊗

    2086 Sex Hormones and their Modulators Profasi; UK: Choragon; Ovitrelle; Pregnyl; USA: Chorex†; Choron; Gonic; who received the drug for a shorter period.6 No association be- 8. Werler MM, et al. Ovulation induction and risk of neural tube Novarel; Ovidrel; Pregnyl; Profasi; Venez.: Ovidrel; Pregnyl; Profasi†. tween gonadotrophin therapy and ovarian cancer was noted in defects. Lancet 1994; 344: 445–6. Multi-ingredient: Ger.: NeyNormin N (Revitorgan-Dilutionen N Nr this study. The conclusions of this study were only tentative, 9. Greenland S, Ackerman DL. Clomiphene citrate and neural tube 65)†; Mex.: Gonakor. defects: a pooled analysis of controlled epidemiologic studies since the numbers who developed ovarian cancer were small; it and recommendations for future studies. Fertil Steril 1995; 64: has been pointed out that a successfully achieved pregnancy may 936–41. reduce the risk of some other cancers, and that the risks and ben- 10. Whiteman D, et al. Reproductive factors, subfertility, and risk efits of the procedure are not easy to balance.7 A review8 of epi- of neural tube defects: a case-control study based on the Oxford Clomifene Citrate (BANM, rINNM) ⊗ Record Linkage Study Register. Am J Epidemiol 2000; 152: demiological and cohort studies concluded that clomifene was 823–8. Chloramiphene Citrate; Citrato de clomifeno; Clomifène, citrate not associated with any increase in the risk of ovarian cancer 11. Sørensen HT, et al. Use of clomifene during early pregnancy de; Clomifeni citras; Clomiphene Citrate (USAN); Klomifeenisi- when used for less than 12 cycles, but noted conflicting results, and risk of hypospadias: population based case-control study.
  • Approach to Breast Mass

    Approach to Breast Mass

    APPROACH TO BREAST MASS Resident Author: Kathleen Doukas, MD, CCFP Faculty Advisor: Thea Weisdorf, MD, CCFP Creation Date: January 2010, Last updated: August 2013 Overview In primary care, breast lumps are a common complaint among women. In one study, 16% of women age 40-69y presented to their physician with a breast lesion over a 10-year period.1 Approximately 90% of these lesions will be benign, with fibroadenomas and cysts being the most common.2 Breast cancer must be ruled out, as one in ten woman who present with a new lump will have cancer.1 Diagnostic Considerations6 Benign: • Fibroadenoma: most common breast mass; a smooth, round, rubbery mobile mass, which is often found in young women; identifiable on US and mammogram • Breast cyst: mobile, often tender masses, which can fluctuate with the menstrual cycle; most common in premenopausal women; presence in a postmenopausal woman should raise suspicion for malignancy; ultrasound is the best method for differentiating between a cystic vs solid structure; a complex cyst is one with septations or solid components, and requires biopsy • Less common causes: Fat necrosis, intraductal papilloma, phyllodes tumor, breast abscess Premalignant: • Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia: Premalignant breast lesions with 4-6 times relative risk of developing subsequent breast cancer;8 often found incidentally on biopsy and require full excision • Carcinoma in Situ: o Ductal Carcinoma in Situ (DCIS): ~85% of in-situ breast cancers; defined as cancer confined to the duct that
  • Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience

    Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience

    Article Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience Eiji Higashihara,*† Vicente E. Torres,*‡ Arlene B. Chapman,§ Jared J. Grantham, Kyongtae Bae,¶ Terry J. Watnick,** †† † ‡‡ ‡‡ ‡‡ 2 Shigeo Horie, Kikuo Nutahara, John Ouyang, Holly B. Krasa, Frank S. Czerwiec, for the TEMPO4 and 156-05-002 Study Investigators Summary †Kyorin University Background and objectives Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of School of Medicine, end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression Mitaka, Tokyo, Japan; ‡ in animal models. Mayo Clinic College of Medicine, Rochester, Minnesota; §Emory Design, setting, participants, and measurements This is a prospectively designed analysis of annual total kid- University School of ney volume (TKV) and thrice annual estimated GFR (eGFR) measurements, from two 3-year studies of Medicine, Atlanta, ʈ tolvaptan in 63 ADPKD subjects randomly matched 1:2 to historical controls by gender, hypertension, age, Georgia; Kansas and baseline TKV or eGFR. Prespecified end points were group differences in log-TKV (primary) and eGFR University Medical Center, Kansas City, (secondary) slopes for month 36 completers, using linear mixed model (LMM) analysis. Sensitivity analyses Kansas; ¶University of of primary and secondary end points included LMM using all subject data and mixed model repeated mea- Pittsburgh School of sures (MMRM) of change from baseline at each year. Pearson correlation tested the association between Medicine, Pittsburgh, log-TKV and eGFR changes. Pennsylvania; **Johns Hopkins University, Baltimore, Maryland; Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced adverse events ††Teikyo University (AEs), with AEs accounting for six of 12 withdrawals.
  • Historical Perspectives on Apple Production: Fruit Tree Pest Management, Regulation and New Insecticidal Chemistries

    Historical Perspectives on Apple Production: Fruit Tree Pest Management, Regulation and New Insecticidal Chemistries

    Historical Perspectives on Apple Production: Fruit Tree Pest Management, Regulation and New Insecticidal Chemistries. Peter Jentsch Extension Associate Department of Entomology Cornell University's Hudson Valley Lab 3357 Rt. 9W; PO box 727 Highland, NY 12528 email: [email protected] Phone 845-691-7151 Mobile: 845-417-7465 http://www.nysaes.cornell.edu/ent/faculty/jentsch/ 2 Historical Perspectives on Fruit Production: Fruit Tree Pest Management, Regulation and New Chemistries. by Peter Jentsch I. Historical Use of Pesticides in Apple Production Overview of Apple Production and Pest Management Prior to 1940 Synthetic Pesticide Development and Use II. Influences Changing the Pest Management Profile in Apple Production Chemical Residues in Early Insect Management Historical Chemical Regulation Recent Regulation Developments Changing Pest Management Food Quality Protection Act of 1996 The Science Behind The Methodology Pesticide Revisions – Requirements For New Registrations III. Resistance of Insect Pests to Insecticides Resistance Pest Management Strategies IV. Reduced Risk Chemistries: New Modes of Action and the Insecticide Treadmill Fermentation Microbial Products Bt’s, Abamectins, Spinosads Juvenile Hormone Analogs Formamidines, Juvenile Hormone Analogs And Mimics Insect Growth Regulators Azadirachtin, Thiadiazine Neonicotinyls Major Reduced Risk Materials: Carboxamides, Carboxylic Acid Esters, Granulosis Viruses, Diphenyloxazolines, Insecticidal Soaps, Benzoyl Urea Growth Regulators, Tetronic Acids, Oxadiazenes , Particle Films, Phenoxypyrazoles, Pyridazinones, Spinosads, Tetrazines , Organotins, Quinolines. 3 I Historical Use of Pesticides in Apple Production Overview of Apple Production and Pest Management Prior to 1940 The apple has a rather ominous origin. Its inception is framed in the biblical text regarding the genesis of mankind. The backdrop appears to be the turbulent setting of what many scholars believe to be present day Iraq.
  • Diversification of Fungal Chitinases and Their Functional Differentiation in 2 Histoplasma Capsulatum 3

    Diversification of Fungal Chitinases and Their Functional Differentiation in 2 Histoplasma Capsulatum 3

    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.09.137125; this version posted June 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 Diversification of fungal chitinases and their functional differentiation in 2 Histoplasma capsulatum 3 4 Kristie D. Goughenour1*, Janice Whalin1, 5 Jason C. Slot2, Chad A. Rappleye1# 6 7 1 Department of Microbiology, Ohio State University 8 2 Department of Plant Pathology, Ohio State University 9 10 11 #corresponding author: 12 [email protected] 13 614-247-2718 14 15 *current affiliation: 16 Division of Pulmonary and Critical Care Medicine 17 University of Michigan 18 VA Ann Arbor Healthcare System, Research Service 19 Ann Arbor, Michigan, USA 20 21 22 running title: Fungal chitinases 23 24 keywords: chitinase, GH18, fungi, Histoplasma 25 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.09.137125; this version posted June 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 26 ABSTRACT 27 Chitinases enzymatically hydrolyze chitin, a highly abundant biomolecule with many potential 28 industrial and medical uses in addition to their natural biological roles. Fungi are a rich source of 29 chitinases, however the phylogenetic and functional diversity of fungal chitinases are not well 30 understood.
  • Evidências Sobre Tratamentos Clínicos Conservadores Para Doença

    Evidências Sobre Tratamentos Clínicos Conservadores Para Doença

    www.rbmfc.org.br ARTIGOS DE REVISÃO Evidências sobre tratamentos clínicos conservadores para doença hemorroidária Evidence on conservative clinical treatments for haemorrhoids Evidencias sobre tratamientos clínicos conservadores para la enfermedad hemorroidal Fernanda da Silva Barbosa. Universidade Federal de Santa Catarina (UFSC). Florianópolis, SC, Brasil. [email protected] (Autora correspondente) Jardel Corrêa de Oliveira. Secretaria Municipal de Saúde (SMS). Florianópolis, SC, Brasil. [email protected] Charles Dalcanale Tesser. Universidade Federal de Santa Catarina (UFSC). Florianópolis, SC, Brasil. [email protected] Resumo Objetivo: o objetivo desta avaliação de tecnologia em saúde foi analisar as evidências sobre tratamentos clínicos conservadores para doença Palavras-chave: Avaliação da Tecnologia hemorroidária utilizáveis na Atenção Primária à Saúde. Métodos: buscou-se no Embase, LILACS e MEDLINE via Pubmed por meta-análises, revisões Biomédica sistemáticas e ensaios clínicos controlados e aleatorizados, publicados até dezembro de 2012, sem limite de linguagem. Os estudos deveriam avaliar Terapêutica os efeitos dos tratamentos clínicos conservadores (fibras ou laxantes, flavonoides, analgésicos, corticosteroides, banhos de assento ou pomadas de Hemorroidas nitroglicerina) comparados a placebo ou entre si. Os desfechos considerados foram: melhora global dos sintomas, sangramento, prurido, dor, prolapso Atenção Primária à Saúde e efeitos adversos. Resultados: uma meta-análise demonstrou que fibras promovem melhora global dos sintomas e do sangramento e diminuem a recorrência após procedimentos ambulatoriais. Três meta-análises mostraram a eficácia de flavonoides para sangramento agudo e pós-operatório, melhora global dos sintomas, exsudação perianal e recorrência após episódio agudo. Não houve diferença estatística para prurido, dor, prolapso ou efeitos adversos nos dois casos. Flavonoides do tipo rutosídeos reduziram sintomas em gestantes, apesar da insuficiência dos dados para comprovar sua segurança.
  • Bodenmikrobiologie (Version: 07/2019)

    Bodenmikrobiologie (Version: 07/2019)

    Langzeitmonitoring von Ökosystemprozessen - Methoden-Handbuch Modul 04: Bodenmikrobiologie (Version: 07/2019) www.hohetauern.at Impressum Impressum Für den Inhalt verantwortlich: Dr. Fernando Fernández Mendoza & Prof. Mag Dr. Martin Grube Institut für Biologie, Bereich Pflanzenwissenschaften, Universität Graz, Holteigasse 6, 8010 Graz Nationalparkrat Hohe Tauern, Kirchplatz 2, 9971 Matrei i.O. Titelbild: Ein Transekt im Untersuchungsgebiet Innergschlöss (2350 m üNN) wird im Jahr 2017 beprobt. © Newesely Zitiervorschlag: Fernández Mendoza F, Grube M (2019) Langzeitmonitoring von Ökosystemprozessen im Nationalpark Hohe Tauern. Modul 04: Mikrobiologie. Methoden-Handbuch. Verlag der Österreichischen Akademie der Wissenschaften, Wien. ISBN-Online: 978-3-7001-8752-3, doi: 10.1553/GCP_LZM_NPHT_Modul04 Weblink: https://verlag.oeaw.ac.at und http://www.parcs.at/npht/mmd_fullentry.php?docu_id=38612 Inhaltsverzeichnis Zielsetzung ...................................................................................................................................................... 1 Inhalt Vorbereitungsarbeit und benötigtes Material ................................................................................................... 2 a. Materialien für die Probenahme und Probenaufbewahrung ................................................................ 2 b. Materialien und Geräte für die Laboranalyse ...................................................................................... 2 Arbeitsablauf ...................................................................................................................................................
  • Aberrant Colourations in Wild Snakes: Case Study in Neotropical Taxa and a Review of Terminology

    Aberrant Colourations in Wild Snakes: Case Study in Neotropical Taxa and a Review of Terminology

    SALAMANDRA 57(1): 124–138 Claudio Borteiro et al. SALAMANDRA 15 February 2021 ISSN 0036–3375 German Journal of Herpetology Aberrant colourations in wild snakes: case study in Neotropical taxa and a review of terminology Claudio Borteiro1, Arthur Diesel Abegg2,3, Fabrício Hirouki Oda4, Darío Cardozo5, Francisco Kolenc1, Ignacio Etchandy6, Irasema Bisaiz6, Carlos Prigioni1 & Diego Baldo5 1) Sección Herpetología, Museo Nacional de Historia Natural, Miguelete 1825, Montevideo 11800, Uruguay 2) Instituto Butantan, Laboratório Especial de Coleções Zoológicas, Avenida Vital Brasil, 1500, Butantã, CEP 05503-900 São Paulo, SP, Brazil 3) Universidade de São Paulo, Instituto de Biociências, Departamento de Zoologia, Programa de Pós-Graduação em Zoologia, Travessa 14, Rua do Matão, 321, Cidade Universitária, 05508-090, São Paulo, SP, Brazil 4) Universidade Regional do Cariri, Departamento de Química Biológica, Programa de Pós-graduação em Bioprospecção Molecular, Rua Coronel Antônio Luiz 1161, Pimenta, Crato, Ceará 63105-000, CE, Brazil 5) Laboratorio de Genética Evolutiva, Instituto de Biología Subtropical (CONICET-UNaM), Facultad de Ciencias Exactas Químicas y Naturales, Universidad Nacional de Misiones, Felix de Azara 1552, CP 3300, Posadas, Misiones, Argentina 6) Alternatus Uruguay, Ruta 37, km 1.4, Piriápolis, Uruguay Corresponding author: Claudio Borteiro, e-mail: [email protected] Manuscript received: 2 April 2020 Accepted: 18 August 2020 by Arne Schulze Abstract. The criteria used by previous authors to define colour aberrancies of snakes, particularly albinism, are varied and terms have widely been used ambiguously. The aim of this work was to review genetically based aberrant colour morphs of wild Neotropical snakes and associated terminology. We compiled a total of 115 cases of conspicuous defective expressions of pigmentations in snakes, including melanin (black/brown colour), xanthins (yellow), and erythrins (red), which in- volved 47 species of Aniliidae, Boidae, Colubridae, Elapidae, Leptotyphlopidae, Typhlopidae, and Viperidae.
  • INDEX to PESTICIDE TYPES and FAMILIES and PART 180 TOLERANCE INFORMATION of PESTICIDE CHEMICALS in FOOD and FEED COMMODITIES

    INDEX to PESTICIDE TYPES and FAMILIES and PART 180 TOLERANCE INFORMATION of PESTICIDE CHEMICALS in FOOD and FEED COMMODITIES

    US Environmental Protection Agency Office of Pesticide Programs INDEX to PESTICIDE TYPES and FAMILIES and PART 180 TOLERANCE INFORMATION of PESTICIDE CHEMICALS in FOOD and FEED COMMODITIES Note: Pesticide tolerance information is updated in the Code of Federal Regulations on a weekly basis. EPA plans to update these indexes biannually. These indexes are current as of the date indicated in the pdf file. For the latest information on pesticide tolerances, please check the electronic Code of Federal Regulations (eCFR) at http://www.access.gpo.gov/nara/cfr/waisidx_07/40cfrv23_07.html 1 40 CFR Type Family Common name CAS Number PC code 180.163 Acaricide bridged diphenyl Dicofol (1,1-Bis(chlorophenyl)-2,2,2-trichloroethanol) 115-32-2 10501 180.198 Acaricide phosphonate Trichlorfon 52-68-6 57901 180.259 Acaricide sulfite ester Propargite 2312-35-8 97601 180.446 Acaricide tetrazine Clofentezine 74115-24-5 125501 180.448 Acaricide thiazolidine Hexythiazox 78587-05-0 128849 180.517 Acaricide phenylpyrazole Fipronil 120068-37-3 129121 180.566 Acaricide pyrazole Fenpyroximate 134098-61-6 129131 180.572 Acaricide carbazate Bifenazate 149877-41-8 586 180.593 Acaricide unclassified Etoxazole 153233-91-1 107091 180.599 Acaricide unclassified Acequinocyl 57960-19-7 6329 180.341 Acaricide, fungicide dinitrophenol Dinocap (2, 4-Dinitro-6-octylphenyl crotonate and 2,6-dinitro-4- 39300-45-3 36001 octylphenyl crotonate} 180.111 Acaricide, insecticide organophosphorus Malathion 121-75-5 57701 180.182 Acaricide, insecticide cyclodiene Endosulfan 115-29-7 79401
  • Remembering Wellness

    Remembering Wellness

    REMEMBERING WELLNESS IN TOUCH FOR HEALTH/KINESIOLOGY A History, Context And Vision For Touch For Health, the First 25 Years And The Next Millennium By JOHN F THIE D.C. We are celebrating the 25th anniversary of the publication of the Touch for Health manual and over 30 years of growth, transition, branching out, and reintegration. We have seen immense benefits in our own lives and in the lives of the people we have touched. And we are now poised for and exponential increase in the growth and untold influence and benefit in health care and human development. Touch for Health Kinesiology is now a global phenomenon and part of the "global village". As we look at our history, our current phase of transition, and our vision of Wellness for the future, we must literally contemplate our most sacred heritage, our most profound beliefs and our highest hopes for the future of all humanity and life on earth. As we look forward to the next 25 years for Touch for Health Kinesiology, and the next millennium for all mankind, we see an unprecedented need for change in the way that we live and care for ourselves, and an unprecedented opportunity for those of us in TFH/K to take a leadership role in fulfilling human needs and effecting change in our lives. Now that people from all walks of life --business, arts, science, religion, etc.-- and among all the healing disciplines-- medicine, chiropractic, faith healing, massage, psychology, etc.-- we are uniquely positioned to contribute in all of these areas. With the current zeitgeist, or spirit of the time, we are uniquely prepared to fulfill the desperately needed role of interface between the health-care practitioner (whether reductionist, disease centered, or holistic, wellness oriented), and personal responsibility, self awareness, and self-care.